TARSUS PHARMACEUTICALS INC (TARS)
US87650L1035 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 224.95M | 71.70M | 171.30M | 168.10M | 58.00M | |||
| Marketable Securities | 2.50M | 145.40M | 500.00K | N/A | N/A | |||
| Receivables | 17.71M | 3.60M | 100.00K | 0.00 | 0.00 | |||
| Inventories | 3.11M | N/A | N/A | N/A | N/A | |||
| Other Current Assets | 7.87M | 4.80M | 4.00M | 2.50M | 0.00 | |||
| Total Current Assets | 256.13M | 225.40M | 176.00M | 170.70M | 58.00M | |||
| Non-Current Assets | ||||||||
| PPE Net | 3.35M | 1.50M | 1.80M | 1.20M | 300.00K | |||
| Investments And Advances | 631.00K | 400.00K | N/A | N/A | N/A | |||
| Intangibles | 3.87M | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 1.51M | 600.00K | 1.10M | 100.00K | 0.00 | |||
| Total Non-Current Assets | 9.36M | 2.50M | 2.90M | 1.30M | 300.00K | |||
| TOTAL ASSETS | 265.49M | 227.90M | 178.90M | 172.00M | 58.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 18.79M | 10.10M | 7.90M | 3.20M | 400.00K | |||
| Accounts Payable | 18.15M | 5.30M | 2.90M | 2.20M | 500.00K | |||
| Other Current Liabilities | N/A | 0.00 | 800.00K | N/A | N/A | |||
| Total Current Liabilities | 36.94M | 15.40M | 11.50M | 5.40M | 800.00K | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 29.82M | 19.40M | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 1.75M | 100.00K | 700.00K | 600.00K | 100.00K | |||
| Total Non-Current Liabilities | 31.57M | 19.60M | 700.00K | 600.00K | 100.00K | |||
| TOTAL LIABILITIES | 68.50M | 35.00M | 12.20M | 6.00M | 900.00K | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -244.66M | -108.80M | -46.70M | -32.80M | -6.00M | |||
| Additional Paid In Capital | 441.64M | 301.70M | 213.40M | 198.80M | 0.00 | |||
| Common Shares | 5.00K | 0.00 | 0.00 | 0.00 | 63.40M | |||
| Other Shareholders' Equity | -2.00K | -100.00K | N/A | N/A | N/A | |||
| Shares Outstanding | 34.21M | 26.70M | 20.70M | 20.50M | 18.80M | |||
| Tangible Book Value per Share | 5.64 | 7.22 | 8.05 | 8.10 | -0.32 | |||
| Total Shareholders' Equity | 196.99M | 192.90M | 166.70M | 166.00M | 57.40M | |||
| TOTAL LIABILITIES AND EQUITY | 265.49M | 227.90M | 178.90M | 172.00M | 58.30M | |||
| Statistics | ||||||||
| Debt/Equity | 0.15 | 0.10 | N/A | N/A | N/A | |||
| Current Ratio | 6.93 | 14.64 | 15.30 | 31.61 | 72.50 | |||
| Return On Assets (ROA) | -51.19% | -27.24% | -7.73% | -15.59% | -8.01% | |||
| Return On Equity (ROE) | -68.99% | -32.19% | -8.30% | -16.15% | -8.14% | |||
All data in USD